Evaluating Ravulizumab for Reducing Delayed Graft Function After Kidney Transplant

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the efficacy and safety of ravulizumab in adult kidney transplant recipients who are at high risk for delayed graft function (DGF). Participants will be randomly assigned to receive either ravulizumab or a placebo intravenously. The primary goal is to measure the time to freedom from dialysis, indicating the severity of DGF. This multicenter approach allows for a diverse patient population and robust data collection.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ≥ 18 years of age at the time of signing the informed consent
* Diagnosed with Dialysis-dependent End-Stage Kidney Disease (ESKD)
* A candidate for kidney transplant from:

  1. Donation after Circulatory Death (DCD) donor
  2. High-risk Donation after Brain Death (DBD) donor

Exclusion Criteria:

* Is to receive a kidney from a donor with category I,II,IV and V Maastricht Classification
* Diagnosed with Acute Kidney Injury (AKI) of Stage 3 severity according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.

Where it's running

• Research Site
  Phoenix, Arizona, United States Recruiting
• Research Site
  Los Angeles, California, United States Recruiting
• Research Site
  San Francisco, California, United States Recruiting
• Research Site
  Stanford, California, United States Recruiting
• Research Site
  New Haven, Connecticut, United States Recruiting
• Research Site
  Jacksonville, Florida, United States Recruiting

+80 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Alexion Pharmaceuticals, Inc. (Sponsor)
• Email: clinicaltrials@alexion.com
• Phone: 1-855-752-2356

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Omnisol-preserved kidneys before transplant (hypothermic machine perfusion)

  This study tests whether using Omnisol during hypothermic machine perfusion before kidney transplant can improve early graft function compared with standard preservation.

  Recruiting Vivalyx GmbH · Rotterdam · NCT07792317

• How Propofol and Sevoflurane Affect miRNA in Living Kidney Donors

  This study tests whether using propofol or sevoflurane during donor nephrectomy changes levels of miRNAs in living kidney donors.

  Recruiting University of Gaziantep · Gaziantep, Sahinbey · NCT07760402

• Intraoperative diuretics during deceased-donor kidney transplants

  This trial tests whether using furosemide or mannitol during kidney transplant surgery affects delayed graft function in adults receiving a deceased-donor kidney.

  Recruiting London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · London, Ontario and 1 other locations · NCT07726134

• Effects of general vs spinal-epidural anesthesia on kidney transplant biomarkers

  This study tests whether sevoflurane general anesthesia or combined spinal-epidural anesthesia changes markers of cellular stress and protective peptides in adults undergoing kidney transplantation.

  Recruiting University of Gaziantep · Gaziantep, State/Province · NCT07678073

• How kidney transplant patients feel about using artificial intelligence in medicine

  This international survey asks adults who have had a kidney transplant how they feel about AI tools that predict graft loss and what it might mean for their daily care.

  Recruiting at 2 sites Paris Translational Research Center for Organ Transplantation · Paris, Île-de-France Region and 1 other locations · NCT07600541

• Ravulizumab for Generalized Myasthenia Gravis in Chinese Adults

  This trial tests ravulizumab in Chinese adults with generalized myasthenia gravis to see if it helps symptoms while checking safety and how the drug behaves in the body.

  Recruiting at 8 sites Phase 3 Alexion Pharmaceuticals, Inc. · Beijing and 9 other locations · NCT07596784

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.